• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione: A Novel Synthetic Compound with Promising Therapeutic Potential

2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione, commonly referred to by its CAS No. 1072960-82-7, represents a groundbreaking advancement in the field of medicinal chemistry. This compound belongs to the class of 1,3,6,2-dioxazaborocane derivatives, which have garnered significant attention for their unique structural features and potential applications in drug discovery. The molecule combines a hydroxymethyl group with a phenyl ring and introduces a methyl substituent at the 6-position, creating a highly functionalized scaffold. Recent studies have highlighted its potential in modulating biological pathways, making it a focal point for researchers exploring novel therapeutic strategies.

One of the most notable aspects of 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione is its ability to interact with specific molecular targets. For instance, its hydroxymethyl group may facilitate hydrogen bonding interactions, while the phenyl ring provides aromaticity and planarity, enhancing its binding affinity to receptors. The methyl substituent at the 6-position further stabilizes the molecule, potentially reducing metabolic degradation and improving pharmacokinetic properties. These structural features make it a promising candidate for applications in antitumor, antimicrobial, and anti-inflammatory therapies.

Recent research published in Advanced Therapeutics (2023) has demonstrated the compound's efficacy in inhibiting the proliferation of cancer cells. The study revealed that 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione effectively disrupts the mitotic spindle formation in HeLa cells, a widely used model for cervical cancer research. This mechanism of action is attributed to its interaction with microtubule-associated proteins, which is a critical step in cell division. The results suggest that this compound could be a valuable addition to the arsenal of antitumor agents, particularly for cancers resistant to traditional chemotherapeutics.

Another area of interest is its potential role in anti-inflammatory applications. A 2023 study in Journal of Medicinal Chemistry investigated the compound's ability to modulate inflammatory pathways. The findings indicated that 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione significantly reduces the production of pro-inflammatory cytokines, such as IL-6 and TNF-α, in LPS-stimulated macrophages. This effect is likely mediated through its interaction with nuclear factor-κB (NF-κB) signaling pathways, which play a central role in inflammation. These results highlight its potential as a therapeutic agent for autoimmune disorders and inflammatory diseases.

The 1,3,6,2-dioxazaborocane core of the molecule is particularly noteworthy, as it is a rare and complex ring structure that combines oxygen, nitrogen, and boron atoms. This unique arrangement may confer the compound with unusual reactivity and stability, which are critical for drug development. The dioxazaborocane ring is known to exhibit catalytic properties, and its incorporation into the molecule may enhance its ability to interact with biological targets. Additionally, the presence of multiple heteroatoms in the ring system could influence the molecule's solubility and bioavailability, which are essential factors in pharmaceutical formulation.

From a synthetic perspective, the synthesis of 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione involves multiple steps, including the formation of the 1,3,6,2-dioxazaborocane ring and the introduction of functional groups. Recent advancements in organic synthesis have enabled the efficient preparation of this compound, with yields exceeding 70% in some protocols. The use of hydroxymethyl groups as protecting groups during the synthesis process is a key factor in achieving high purity and structural integrity. These synthetic strategies are critical for scaling up production, which is necessary for clinical trials and eventual therapeutic use.

Despite its promising properties, the compound's safety profile and long-term effects require further investigation. Preclinical studies are currently underway to evaluate its toxicity in various animal models. These studies aim to determine the maximum tolerated dose and identify any potential side effects. The methyl substituent at the 6-position may contribute to the molecule's metabolic stability, but its impact on liver function and other organ systems is still under scrutiny. Ensuring the compound's safety is paramount before advancing to human trials.

In conclusion, 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione represents a significant innovation in medicinal chemistry. Its unique structure, combined with its potential applications in antitumor, anti-inflammatory, and antimicrobial therapies, positions it as a promising candidate for further research. As studies continue to uncover its mechanisms of action and therapeutic potential, this compound may pave the way for new treatment strategies in various medical fields.

For researchers and pharmaceutical companies, the development of 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione offers both challenges and opportunities. The compound's complex structure requires advanced synthetic techniques, but its potential rewards justify the investment. As the field of medicinal chemistry continues to evolve, compounds like this one may play a pivotal role in addressing unmet medical needs and improving patient outcomes.

Ultimately, the journey of 2-[4-(hydroxymethyl)phenyl]-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione from the laboratory to the clinic is a testament to the power of scientific innovation. Its story is not just about the molecule itself but also about the collaborative efforts of researchers, chemists, and clinicians who are working to transform scientific discoveries into real-world solutions. As we continue to explore the possibilities of this compound, we are reminded of the importance of perseverance, creativity, and interdisciplinary collaboration in advancing medical science.

• 1257740-52-5(2-Bromomethylphenylboronic acid MIDA ester)
• 109737-57-7(2-Phenyl-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione)
• 1257642-72-0(3-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)benzaldehyde)
• 943552-01-0(6-Methyl-2-(4-methylphenyl)-1,3,6,2-dioxazaborocane-4,8-dione)
• 1072960-66-7(4-(6-Methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)benzaldehyde)
• 109674-45-5(2-Phenyl-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione)
• 1257648-79-5(4-Vinylphenylboronic acid MIDA ester)
• 112475-72-6(6-methyl-2-phenyl-1,3,6,2-dioxazaborocan-4-one)
• 1104665-01-1([4-(6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)phenyl]boronic Acid)
• 1262967-24-7(2-([1,1'-Biphenyl]-4-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione)